Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Reexamination Certificate
2006-05-30
2006-05-30
Stucker, Jeffrey (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
C424S204100, C424S206100, C424S209100, C424S278100, C514S002600
Reexamination Certificate
active
07052701
ABSTRACT:
The invention relates to nasal or oral administration of a compound containing inactivated influenza virus antigen and aluminum as adjuvant for the prophylaxis of influenza virus infections. Said vaccine is especially suitable for inducing a mucosal IgA immune response and systemic IgG immune response.
REFERENCES:
patent: 4981782 (1991-01-01), Judd et al.
patent: 5136019 (1992-08-01), Judd et al.
patent: 5243030 (1993-09-01), Judd et al.
patent: 5976552 (1999-11-01), Volvovitz
patent: 6635246 (2003-10-01), Barrett et al.
patent: 6861244 (2005-03-01), Barrett et al.
patent: WO97/49423 (1931-12-01), None
patent: WO94/19013 (1994-09-01), None
patent: WO96/15231 (1996-05-01), None
patent: WO96/40290 (1996-12-01), None
patent: WO99/24068 (1999-05-01), None
patent: WO00/15251 (2000-03-01), None
Vogel, F.R., Powell, M.F., 1995. A compendium of vaccine adjuvants and excipients. In: Powell, M.F. Newman, M.J. (Eds.), Vaccine Design. The Subunit and Adjuvant Approach. Plenum, New York, pp. 3-10 and 93-96.
McKenzie et al. “Mucosal Immunity: Overcoming the Barrier for Induction of Proximal Responses” Immunologic Research vol. 30, No. 1 (2004), pp. 35-47.
Moschos et al. “Adjuvant synergy: The effects of nasal coadmin-istration of adjuvants” Immunology and Cell Biology vol. 82 (2004), pp. 628-637.
Lynch et al. “Increased Protection against Pneumococcal Disease by Mucosal Administration of Conjugate Vaccine plus Interleukin-12” Infection and Immunity, vol. 71, No. 8 (Aug. 2003), p. 4780-4788.
Avtushenko et al. Journal of Biotechnology 44: 21-28 (1996).
Belshe et al. New England Journal of Medicine 338(20): 1405-1412 (1998).
Chen et al. Current Topics in Microbiology and Immunology 146: 101-106 (1989).
Couch et al. Journal of Infectious Diseases 176: 38-44 (1997).
Davenport et al. The Journal of Immunology 100(5): 1139-1140 (1968).
De Hann et al. Vaccine 13(2): 155-162 (1995).
Komase et al. Vaccine 16(2/3): 248-254 (1998).
Liew et al. Eur. J. Immunol. 14: 350-356 (1984).
Oka et al. Vaccine 8: 573-576 (1990).
Oka et al. Vaccine 12(14): 1255-1258 (1994).
Palmer et al. A Procedural Guide to the Performance of Rubella Hemagglutination-Inhibition Tests. U.S. Dept. of Health, Education and Welfare, Immunology Series No. 2 Revised, pp. 25-62 (1977).
Tamura et al. The Journal of Immunology 149(3): 981-988 (1992).
Waldman Nature 218: 594-595 (1968).
Wood Journal of Biological Standardization 5: 237-247 (1977).
Aebischer et al Infect. Immun. 68: 1328-1336 (Mar. 2000).
Sachdeva et al. Infect. Immun. 72: 5775-5782 (Oct. 2004).
Verschoor et al. J. Virol. 73: 3292-3300 (Apr. 1999).
Barrett Noel
Dorner Friedrich
Gerencer Marijan
Kistner Otfried
Baxter Healthcare S.A.
Heller Ehrman LLP
Stucker Jeffrey
LandOfFree
Inactivated influenza virus vaccine for nasal or oral... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inactivated influenza virus vaccine for nasal or oral..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inactivated influenza virus vaccine for nasal or oral... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3651836